Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $57.9 million.

  • Ultragenyx Pharmaceutical's Other Non-Current Assets rose 740.45% to $57.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.9 million, marking a year-over-year increase of 740.45%. This contributed to the annual value of $62.7 million for FY2024, which is 865.91% up from last year.
  • As of Q3 2025, Ultragenyx Pharmaceutical's Other Non-Current Assets stood at $57.9 million, which was up 740.45% from $60.1 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Other Non-Current Assets ranged from a high of $62.7 million in Q4 2024 and a low of $8.9 million during Q1 2021
  • In the last 5 years, Ultragenyx Pharmaceutical's Other Non-Current Assets had a median value of $27.9 million in 2023 and averaged $37.5 million.
  • In the last 5 years, Ultragenyx Pharmaceutical's Other Non-Current Assets skyrocketed by 38222.31% in 2021 and then surged by 400.7% in 2025.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Other Non-Current Assets stood at $20.6 million in 2021, then surged by 135.13% to $48.3 million in 2022, then grew by 19.34% to $57.7 million in 2023, then rose by 8.66% to $62.7 million in 2024, then fell by 7.69% to $57.9 million in 2025.
  • Its Other Non-Current Assets was $57.9 million in Q3 2025, compared to $60.1 million in Q2 2025 and $62.4 million in Q1 2025.